BIO 2022: ‘Limitless’ Innovation Is Harder With Limited Cash
Executive Summary
The mid-year meeting offered a chance to reflect on the tumultuous times and look at how the biopharma industry can weather the storm.
You may also be interested in...
J&J’s Gorsky Offers Leadership Lessons As He Gets Set To Advise Apple
After 34 years of seeing and shaping Johnson & Johnson’s future, executive chair Alex Gorsky has recently joined Apple’s board of directors. At a recent event, he shared lessons for future leaders while unraveling some of the thinking behind decisions taken as chair and CEO
Third Rock Thinks Its Model Reassures Investors In Difficult Times
New fund will include some later-stage investments in portfolio companies, in recognition of the currently tough environment for privately held biotechs.
BIO 2022 Notebook: Deal Values In The Eyes Of The Beholders
News and views from day three of the BIO annual meeting include business development insights, such as Sanofi's global head of BD Alban De La Sabliere's promise that big pharma has no hidden agenda and an AbbVie BD exec's observations that lower company valuations have not led to lower asking prices. Also, BIO chairman and Nkarta CEO Paul Hastings' optimism that biotech will rebound and Venus Williams' Sjogren's disease story draws a crowd.